Pharma & Biotech VC & Investment News
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Today's issue
Refine Search
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Pharmaceutical
Syndax Pharmaceuticals has entered into a $350 million royalty funding agreement with Royalty Pharma. 6 November 2024
Biotechnology
A new Seattle-based biotech company has the best endorsement imaginable as it emerges from stealth. Archon Biosciences’ platform, leveraging AI-driven advances in computational protein design, were recognized earlier this month by the awarding of the 2024 Nobel Prize in Chemistry, for its ability to create novel proteins with desired functions. 31 October 2024
Biotechnology
As interest in advanced therapies continues to surge, a new ophthalmic specialist focused on cell-based medicines has been launched with $70 million in series A financing. 13 July 2023
Biotechnology
Boston, USA-based Crossbow Therapeutics, a biotech developing a new class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding round. 12 July 2023
Biotechnology
Among important research news last week, UK pharma major AstraZeneca released the first Phase III data on its lung cancer candidate datopotamab (Dato-DXd). On the regulatory front, US drugmaker Amneal Pharmaceuticals suffered a setback when the US Food and Drug Administration (FDA) issued a complete response letter (CRL) on its Parkinson’s disease candidate IPX203. Also, the FDA handed full approval to Eisai and Biogen's Alzheimer's treatment Leqembi last Thursday following a study that verified the drug's ability to slow cognitive decline in the early stages of the disease, a decision that opened the door for broader Medicare coverage of the treatment. US pharma giant Pfizer acquired $25 million worth of stock in Caribou Biosciences, a gene-editing company, which will help in the development of the latter’s CB-011 in multiple myeloma. 9 July 2023
Biotechnology
US pharma giant Pfizer has made a $25 million equity investment in Caribou Biosciences, a Californian CRISPR genome-editing company. 7 July 2023
Pharmaceutical
The UK-based non-profit medical research organization and charity LifeArc has announced a program to invest more than £100 million ($127 million) by 2030 to deliver new breakthroughs in rare diseases. 6 July 2023
Pharmaceutical
The Foreign Direct Investment (FDI) equity inflow into the pharmaceutical industry in India has jumped by 45.4% in the fiscal year ended March 2023, compared to inflow in the previous fiscal year. 6 July 2023
Biotechnology
French clinical-stage developer of immunotherapies Exeliom Biosciences today announced the completion of its 24 million-euro ($26 million) Series A financing to progress the clinical development of its therapeutic pipeline. 30 June 2023
Biotechnology
Chinese biotech Laekna has listed on the main board of Hong Kong’s stock exchange. 29 June 2023
Biotechnology
Aeglea BioTherapeutics has acquired Spyre Therapeutics, a privately-held biotech advancing antibody therapeutics aimed at transforming the treatment of inflammatory bowel disease (IBD). 22 June 2023
Biotechnology
Massachusetts, USA-based biotech funder and incubator Flagship Pioneering today unveiled its latest new company, Empress Therapeutics. 21 June 2023
Pharmaceutical
The appointment of a new chief executive at immune-mediated disease specialist Veralox Therapeutics coincides with a fresh investment of $24 million from new and existing backers. 20 June 2023
Pharmaceutical
An investment bank for the UK government has highlighted what it sees as the success of the UK life science sector in raising venture capital in recent years. 15 June 2023
Biotechnology
San Diego, USA-base next-gen gene therapy developer Kate Therapeutics (KateTx) has emerged from stealth mode with a $51 million Series A financing. 9 June 2023
Biotechnology
German radiopharmaceutical biotech ITM Isotope Technologies has announced an equity investment round of 255 million euros ($273 million) led by Temasek. 9 June 2023
Biotechnology
A series B financing round will swell the coffers of Massachusetts, USA-based biotech Upstream Bio to the tune of $200 million. 8 June 2023
Biotechnology
California, USA-based biotech start-up Bitterroot Bio has emerged from stealth with a $145 million Series A financing. 8 June 2023
Biotechnology
Phase II results from Austrian arenaviral technology firm Hookipa Pharma show a 43% objective response rate (ORR) for its lead candidate in head and neck cancer. 2 June 2023
Biotechnology
California, USA-based biotech start-up Eikon Therapeutics has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. 2 June 2023
Biotechnology
US clinical-stage biotech Carmot Therapeutics has announced a $150 million oversubscribed and up-sized Series E financing. 27 May 2023
Biotechnology
Boston, USA-based cell and gene therapy incubator ElevateBio has raised $401 million in a series D financing round led by AyurMaya Capital Management Fund. 24 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze